Abstract

<div>AbstractPurpose:<p>The natural history and prognosis of appendiceal adenocarcinomas differ from those of adenocarcinomas arising in other large bowel sites. We aimed to compare the molecular profiles exhibited by appendiceal adenocarcinomas and colorectal cancers, or between the histopathologic subtypes of appendiceal adenocarcinoma.</p>Experimental Design:<p>A total of 183 samples from appendiceal adenocarcinoma [46 adenocarcinoma, not otherwise specified (NOS), 66 pseudomyxoma peritonei (PMP), 44 mucinous adenocarcinoma (MU), and 27 signet ring cell carcinoma (SR)], 994 from right-sided colorectal cancer (R-CRC), and 1,080 from left-sided CRC (L-CRC) were analyzed by next-generation sequencing (NGS) and IHC markers. Microsatellite instability (MSI) and tumor mutational burden (TMB) were tested by NGS, and programmed death ligand 1 (PD-L1) by IHC.</p>Results:<p>We observed high mutation rates in appendiceal adenocarcinoma samples for <i>KRAS</i> (55%), <i>TP53</i> (40%), <i>GNAS</i> (31%), <i>SMAD4</i> (16%), and <i>APC</i> (10%). Appendiceal adenocarcinoma exhibited higher mutation rates in <i>KRAS</i> and <i>GNAS</i>, and lower mutation rates in <i>TP53, APC</i>, and <i>PIK3CA</i> (6%) than colorectal cancers. PMP exhibited much higher mutation rates in <i>KRAS</i> (74%) and <i>GNAS (</i>63%), and much lower mutation rates in <i>TP53</i> (23%), <i>APC</i> (2%), and <i>PIK3CA</i> (2%) than NOS. Alterations associated with immune checkpoint inhibitor response (MSI-high, TMB-high, PD-L1 expression) showed similar frequency in appendiceal adenocarcinoma compared with L-CRC, but not R-CRC, and those of NOS were higher than other subtypes of appendiceal adenocarcinoma and L-CRC.</p>Conclusions:<p>Molecular profiling of appendiceal adenocarcinoma revealed different molecular characteristics than noted in R-CRC and L-CRC, and molecular heterogeneity among the histopathologic subtypes of appendiceal adenocarcinoma. Our findings may be critical to developing an individualized approach to appendiceal adenocarcinoma treatment.</p></div>

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.